Immune checkpoint inhibitors (ICIs) are thought to restore tumor immune surveillance by targeting the programmed cell death-1 receptor (PD1; nivolumab and pembrolizumab) on exhausted CD8+ T cells or the programmed cell death-1 ligand 1 (PDL1; atezolizumab) [23,24,25,26]. Here, CD274 is linked to neoplasm.